> Boehringer Ingelheim partnered with Inflammasome Therapeutics to develop up to three retinal disease therapies. The candidates will use Inflammasome’s intravitreal delivery technologies to get Boehringer molecules to retinal targets. Statement
> GenSight Biologics shared more data on its Leber hereditary optic neuropathy gene therapy. The biotech plans to file for approval in Europe in the third quarter of 2020. Release
> Tacalyx raised €7 million ($7.7 million) to generate anti-tumor associated carbohydrate antigen cancer therapies. Boehringer Ingelheim Venture Fund and Kurma Partners co-led the round. Statement
> Kadimastem shared data from a phase 1/2a trial of its cell therapy in amyotrophic lateral sclerosis. Release
> T3 Pharmaceuticals raised CHF 12 million (€11 million) to move its lead drug into the clinic next year. The candidate is a bacterium engineered to grow and produce therapeutic proteins in solid tumors. Statement
> The FDA set a late February PDUFA date for Acacia Pharma’s Barhemsys. Release